HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT

References

• Clarkson TB, Mele GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause 2013;20:342–53
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Manson JE, Kaunitz AM, Anderson GL. Lessons learned from the Women 's Health Initiative Trials of menopausal hormone therapy. Obstet Gynecol 2013;121:172–6
   PubMed Web of Science ®Google Scholar
• L’Hermite M, Simoncini T, Fuller S, Genazzani AR. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.0Maturitas 2008;60:185–201
   PubMed Web of Science ®Google Scholar
• Gompel A. Micronized progesterone and its impact on the endometrium and breast vs. progestogens. Climacteric 2012;15(Suppl 1):18–25
   PubMed Web of Science ®Google Scholar
• Mueck A. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric 2012;15(Suppl 1):11–17
   PubMedGoogle Scholar
• Salpeter SR, Buckley NS, Liu H, Salpeter EE. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med 2009;122:42–52
   PubMed Web of Science ®Google Scholar
• Hunter MS, Gentry-Maharaj A, Ryan A, et al. Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10,418 British women aged 54–65. Br J Obstet Gynaecol 2012;119:40–50
   Google Scholar
• Freeman EW, Sammel MD, Lin H, Liu Z, Gracia CR. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol 2011;117:1095–104
   PubMed Web of Science ®Google Scholar
• Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365:1543–51
   PubMed Web of Science ®Google Scholar
• Jaakkola S, Lyytinen HK, Dyba T, Ylikorkala O, Pukkala E. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study. Int J Cancer 2011;128:1644–51
   PubMed Web of Science ®Google Scholar
• Trabert B, Wentzensen N, Yang HP, et al. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?Int J Cancer 2013;132:417–26
   PubMed Web of Science ®Google Scholar
• Kuhl H, Schneider HPG. Progesterone – promoter or inhibitor of breast cancer. Climacteric 2013;16(Suppl 1):1–15
   PubMedGoogle Scholar
• Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol 2010;172:1394–403
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.JAMA 1996;275:370–5
   PubMed Web of Science ®Google Scholar
• Bourgain C, Devroey P, Van Waesberghe l, Smitz J, Van Steirteghem A. Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure. Hum Reprod 1990;5:537–43
   PubMed Web of Science ®Google Scholar
• Moyer DL, de Lignières B, Driguez P, Pez JP. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril 1993;59:992–7
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Hapgood JP, Winer S, Mishell DR, Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev 2013;34:171–208
   PubMed Web of Science ®Google Scholar
• Løkkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Liddegaar O. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 2008;29:2660–8
   PubMed Web of Science ®Google Scholar
• Wild RA, Wu C, Curb JD, et al. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause 2013;20:254–60
   PubMed Web of Science ®Google Scholar
• Chu MC, Cosper P, Nakhuda GS, Lobo R. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. Fertil Steril 2006;86: 1669–75
   PubMed Web of Science ®Google Scholar
• Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004;47:1175–87
   PubMed Web of Science ®Google Scholar
• de Lauzon-Guillain B, Fournier A, Fabre A, et al. Menopausal hormone therapy and new-onset diabetes in the French Etude Epidémiologique de Femmes de la Mutuelle Générale de l’Education Nationale (E3N) cohort. Diabetologia 2009;52: 2092–100
   PubMed Web of Science ®Google Scholar
• Fenkci S. Effects of short-term transdermal hormone replacement therapy on glycaemic control, lipid metabolism, C-reactive protein and proteinuria in postmenopausal women with type 2 diabetes or hypertension. Hum Reprod 2003;18:866–70
   PubMed Web of Science ®Google Scholar
• Lobo RA. What is the effect of estrogen on blood pressure after menopause?Menopause 2006;13:331–3
   PubMed Web of Science ®Google Scholar
• Gerber LM, Sievert LL, Warren K, Pickering TG, Schwartz JE. Hot flashes are associated with increased ambulatory systolic blood pressure. Menopause 2007;14:308–15
   PubMed Web of Science ®Google Scholar
• Lee D-Y, Kim J-Y, Kim J-H, et al. Effects of hormone therapy on ambulatory blood pressure in postmenopausal Korean women. Climacteric 2011;14:92–9
   PubMed Web of Science ®Google Scholar
• Mercuro G, Zoncu S, Piano D, et al. Estradiol-17β reduces blood pressure and restores the normal amplitude of the circadian blood pressure rhythm in postmenopausal hypertension. Am J Hypertens 1998;11:909–13
   PubMed Web of Science ®Google Scholar
• Liu B, Beral V, Balkwill A, Green J, Sweetland S, Reeves G. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. Br Med J 2008;337:a386(9p)
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Plu-Bureau G, Menard J, et al. Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab 2007;92:2074–9
   PubMed Web of Science ®Google Scholar
• Canonico M, Plu-Bureau G, Lowe GDO, Scarabin P-Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. Br Med J 2008;336:1227–31
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell’Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979–86
   PubMed Web of Science ®Google Scholar
• Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340–5
   PubMed Web of Science ®Google Scholar
• Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.Menopause 2011;18:1052–9
   PubMed Web of Science ®Google Scholar
• Sweetland S, Beral V, Balkwill A, et al. Venous thromboembolism risk in relation to different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost 2012; 10:2277–86
   PubMed Web of Science ®Google Scholar
• Rocca WA, Grossardt BR, Miller VM, Shuster LT, Brown RD. Premature menopause or early menopause and risk of ischemic stroke. Menopause 2012;19:272–7
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–78
   PubMed Web of Science ®Google Scholar
• Bath PMW, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. Br Med J 2005;330:342–5
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell’Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. Br Med J 2010;340:c2519(7p)
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JAE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168:861–6
   PubMed Web of Science ®Google Scholar
• White RH. The epidemiology of venous thromboembolism. Circulation 2003;107(Suppl 1):I4–8
   Google Scholar
• ACOG Committee Opinion No 556. Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol 2013;121:887–90
   PubMedGoogle Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. Br Med J 2012; 345:e6409(11p)
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995;273:199–208
   PubMed Web of Science ®Google Scholar
• Canonico M, Plu-Bureau G, Scarabin P-Y. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Maturitas 2011;70:354–60
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840–5
   PubMed Web of Science ®Google Scholar
• Løkkegaard E, Jovanovic Z, Heitmann B, et al. Increased risk of stroke in hypertensive women using hormone therapy. Arch Neurol 2003;60:1379–84
   PubMed Web of Science ®Google Scholar
• Lobo RA, Clarkson TB. Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women. Menopause 2010;18:237–40
   Web of Science ®Google Scholar
• Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 2012;15:241–9
   PubMed Web of Science ®Google Scholar
• Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev 2013;34:130–62
   PubMed Web of Science ®Google Scholar
• Boyd NF, Rommens JM, Vogt K, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 2005;10:798–808
   Google Scholar
• Boyd N, Martin L, Chavez S, et al. Breast-tissue composition and other risk factors for breast cancer in young women: a cross-sectional study. Lancet Oncol 2009;10:569–80
   PubMed Web of Science ®Google Scholar
• Martin LJ, Boyd NF. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence.Breast Cancer Res 2008;10:201(14p)
   PubMed Web of Science ®Google Scholar
• Harvey JA, Santen RJ, Petroni GR, et al. Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices. Menopause 2008;15:67–73
   PubMed Web of Science ®Google Scholar
• Vachon CM, Sasano H, Ghosh K, et al. Aromatase immunoreactivity is increased in mammographically dense regions of the breast. Breast Cancer Res Treat 2011;125:243–52
   PubMed Web of Science ®Google Scholar
• Isaksson E, Sahlin L, Söderqvist G, et al. Expression of sex steroid receptors and IGF-1 mRNA in breast tissue – effects of hormonal treatment. J Steroid Biochem Mol Biol 1999;70: 257–62
   PubMed Web of Science ®Google Scholar
• Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30–7
   PubMed Web of Science ®Google Scholar
• Greendale G, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999;130:262–9
   PubMed Web of Science ®Google Scholar
• Ursin G, Palla SL, Reboussin BA, et al. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Clin Oncol 2004;22:2842–8
   PubMed Web of Science ®Google Scholar
• Martin LJ, Minkin S, Boyd NF. Hormone therapy, mammographic density, and breast cancer risk. Maturitas 2009;64: 20–6
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11
   PubMed Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009;113:65–73
   PubMed Web of Science ®Google Scholar
• Fournier A, Fabre A, Mesrine S, Boutron-Ruault M-C, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008;26:1260–8
   PubMed Web of Science ®Google Scholar
• Chang KL, Lee TTY, Linares-Cruz G, Fournier S, de Lignières B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 1995;63:785–91
   PubMed Web of Science ®Google Scholar
• Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963–9
   PubMed Web of Science ®Google Scholar
• Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 2007;101:125–34
   PubMed Web of Science ®Google Scholar
• Wood CE, Register TC, Cline JM. Transcriptional profiles of progestogen effects in the postmenopausal breast. Breast Cancer Res Treat 2009;114:233–42
   PubMed Web of Science ®Google Scholar
• Murkes D, Conner P, Leifland K, et al. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil Steril 2011;95: 1188–91
   PubMed Web of Science ®Google Scholar
• Murkes D, Lalitkumar PGL, Leifland K, Lundström E, Derqvist G. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo. Gynecol Endocrinol 2012;28:12–15
   PubMed Web of Science ®Google Scholar
• Courtin A, Communal L, Vilasco M, et al. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat 2012;131:49–63
   PubMed Web of Science ®Google Scholar
• Campagnoli C, Abbà C, Ambroggio S, Peris C. Pregnancy, progesterone and progestins in relation to breast cancer risk. J Steroid Biochem Mol Biol 2005;97:441–50
   PubMed Web of Science ®Google Scholar
• Beral V, Reeves G, Bull D, Green J. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011;103:296–305
   PubMed Web of Science ®Google Scholar
• Fournier A, Mesrine S, Boutron-Ruault M-C, Clavel-Chapelon F. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?J Clin Oncol 2009;27:5138–43
   PubMed Web of Science ®Google Scholar
• NAMS Position Statement .The 2012 hormone therapy position statement of the North American Menopause Society. Menopause 2012;19:257–71
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316–37
   PubMed Web of Science ®Google Scholar
• Karim R, Dell RM, Greene DF, Mack WJ, Gallagher JC, Hodis HN. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 2011;18:1172–7
   PubMed Web of Science ®Google Scholar
• Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(Suppl 1):s1–66
   PubMed Web of Science ®Google Scholar